IRIDEX (NASDAQ:IRIX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note published on Monday. The firm issued a hold rating on the medical equipment provider’s stock.

IRIDEX Stock Up 1.8 %

Shares of NASDAQ:IRIX opened at $1.66 on Monday. IRIDEX has a fifty-two week low of $1.27 and a fifty-two week high of $3.65. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The firm’s 50-day simple moving average is $1.73 and its 200-day simple moving average is $1.79. The company has a market cap of $27.62 million, a price-to-earnings ratio of -2.48 and a beta of 0.82.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. The business had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same quarter in the previous year, the company earned ($0.11) earnings per share.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.